Cas:313223-18-6 Nickel(II) bromide hydrate manufacturer & supplier

We serve Chemical Name:Nickel(II) bromide hydrate CAS:313223-18-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

Nickel(II) bromide hydrate

Chemical Name:Nickel(II) bromide hydrate
CAS.NO:313223-18-6
Synonyms:EINECS 236-665-0;MFCD00011141
Molecular Formula:NiBr2·3H2O
Molecular Weight:218.50
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:
Exact Mass:215.772003
LogP:

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like EINECS 236-665-0 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00011141 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00011141 Use and application,MFCD00011141 technical grade,usp/ep/jp grade.


Related News: This also includes experience for drug delivery systems, efficient teams, facilities, and production capabilities. 6-[Difluoro[6-(1-methyl-1H-pyrazol-4-yl)-1,2,4-triazolo[4,3-b]pyridazin-3-yl]methyl]-quinoline hydrochloride manufacturers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. 1-Chloro-5-iodo-2-methyl-4-nitrobenzene suppliers The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus. 2-(2,5-Dichlorophenoxy)-2-methylpropanoyl chloride vendor & factory Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.”,The CDC’s delay likely came as a disappointment to representatives for the immunocompromised community, who pleaded with the CDC’s expert group to give the go-ahead for booster use in these people, who do not mount a strong enough defense against the virus.